DK0958371T3 - Cytopatiske vira til behandling og forebyggelse af neoplasi - Google Patents

Cytopatiske vira til behandling og forebyggelse af neoplasi

Info

Publication number
DK0958371T3
DK0958371T3 DK97951519T DK97951519T DK0958371T3 DK 0958371 T3 DK0958371 T3 DK 0958371T3 DK 97951519 T DK97951519 T DK 97951519T DK 97951519 T DK97951519 T DK 97951519T DK 0958371 T3 DK0958371 T3 DK 0958371T3
Authority
DK
Denmark
Prior art keywords
replication phenotype
cells
neoplastic cells
viral
neoplastic
Prior art date
Application number
DK97951519T
Other languages
Danish (da)
English (en)
Inventor
James R Bischoff
Julie Nye
Ng Lelia
Sharon Horn
Angelica Williams
David Kirn
Original Assignee
Onyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharma Inc filed Critical Onyx Pharma Inc
Application granted granted Critical
Publication of DK0958371T3 publication Critical patent/DK0958371T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK97951519T 1996-12-31 1997-12-10 Cytopatiske vira til behandling og forebyggelse af neoplasi DK0958371T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3461596P 1996-12-31 1996-12-31
PCT/US1997/022036 WO1998029555A2 (en) 1996-12-31 1997-12-10 Cytopathic viruses for therapy and prophylaxis of neoplasia

Publications (1)

Publication Number Publication Date
DK0958371T3 true DK0958371T3 (da) 2004-04-13

Family

ID=21877522

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97951519T DK0958371T3 (da) 1996-12-31 1997-12-10 Cytopatiske vira til behandling og forebyggelse af neoplasi

Country Status (11)

Country Link
US (1) US6080578A (ja)
EP (1) EP0958371B1 (ja)
JP (1) JP4225577B2 (ja)
AT (1) ATE256195T1 (ja)
AU (1) AU723604B2 (ja)
CA (1) CA2273825C (ja)
DE (1) DE69726759T2 (ja)
DK (1) DK0958371T3 (ja)
ES (1) ES2212815T3 (ja)
PT (1) PT958371E (ja)
WO (1) WO1998029555A2 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
WO1999059604A1 (en) * 1998-05-15 1999-11-25 Onyx Pharmaceuticals, Inc. Adenovirus-chemotherapeutic combination for treating cancer
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
AU7809601A (en) * 2000-08-03 2002-02-18 Onyx Pharma Inc Adenovirus e1b-55k single amino acid mutants and methods of use
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
JP2004536607A (ja) * 2001-07-23 2004-12-09 オニックス ファーマシューティカルズ，インコーポレイティド 標的化されたヒト癌細胞において選択的に複製するウイルス変異体
JP4354814B2 (ja) * 2001-09-29 2009-10-28 ヨンセイ ユニバーシティ 改善された疾患治療効果を有する組換えアデノウィルス及びそれを含む薬剤学的組成物
US20060099178A1 (en) 2002-05-27 2006-05-11 Holm Per S Novel use of adenoviruses and nucleic acids coding therefor
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
WO2004042025A2 (en) 2002-11-01 2004-05-21 Cell Genesys, Inc. Cell-specific adenovirus vector comprising ebv-specific promoter
JP2006519784A (ja) * 2003-01-28 2006-08-31 シャンハイ、サンウエイ、バイアテク、カムパニ、リミティド 原発癌および転移癌に対する治療（ａ２）温熱療法と腫瘍溶解の同時治療（ａ３）
CN1934253A (zh) * 2003-07-18 2007-03-21 昂尼克斯药物公司 用于治疗疾病的b亚组腺病毒载体
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
WO2005086922A2 (en) * 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
KR102081567B1 (ko) 2012-01-25 2020-02-26 디엔에이트릭스, 인코포레이티드 바이오마커 및 종양분해 바이러스 및 면역 조절을 사용한 병용 치료요법
ES2759785T3 (es) 2012-02-02 2020-05-12 Univ Texas Adenovirus que expresan antígenos oncógenos heterólogos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
AU682854B2 (en) * 1993-02-16 1997-10-23 Onyx Pharmaceuticals Cytopathic viruses for therapy and prophylaxis of neoplasia

Also Published As

Publication number Publication date
JP2001508290A (ja) 2001-06-26
DE69726759T2 (de) 2005-01-13
WO1998029555A2 (en) 1998-07-09
EP0958371B1 (en) 2003-12-10
DE69726759D1 (de) 2004-01-22
CA2273825A1 (en) 1998-07-09
PT958371E (pt) 2004-04-30
WO1998029555A3 (en) 1998-10-01
ES2212815T3 (es) 2004-08-01
AU723604B2 (en) 2000-08-31
JP4225577B2 (ja) 2009-02-18
AU5514598A (en) 1998-07-31
ATE256195T1 (de) 2003-12-15
CA2273825C (en) 2011-02-08
EP0958371A2 (en) 1999-11-24
US6080578A (en) 2000-06-27

Similar Documents

Publication Publication Date Title
DK0689447T3 (da) Cytopatiske vira til behandling af og profylakse for neoplasia
DK0958371T3 (da) Cytopatiske vira til behandling og forebyggelse af neoplasi
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
DK1252323T3 (da) Virus-stammer til den onkolytiske behandling af cancer
HUP0400882A2 (hu) Onkolitikus vírusterápia
NO933171L (no) Anvendelse av molekyler rettet mot celleoverflatereseptorer for behandling av virussykdommer
NO922949L (no) Forbindelser og fremgangsmaater for inhibering av hiv- og beslektede virus
DE69133022T2 (de) Viral verursachte Zerstörung von Neoplastzellen
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
MXPA02007271A (es) Compuestos de tipo pirrol, composiciones que los contienen, y metodos para el tratamiento de cancer o enfermedades virales.
DK0652957T3 (da) Samlede viruspartikler og deres anvendelse i en vaccine imod rotaviral sygdom
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
MXPA02000969A (es) Vacuna de virus de inmuno-deficiencia humana atenuado controlado en forma condicional.
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
DE69730153D1 (de) EHV-1 Vektoren
AU2001278139A1 (en) Enhanced replication of hcv rna
Elliot-Lopez Treatment news: new options for the future
James T-20 and Trimeris
JPH02275819A (ja) エイズ原因ウィルスに対する抗ウィルス剤
UA9737A (uk) Спосіб відновлення прохідності стравоходу
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.